Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.

@article{Kuter2012HealthrelatedQO,
  title={Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.},
  author={David J Kuter and Susan D. Mathias and Mathias J. Rummel and Romeo A. Mandanas and Aristoteles A N Giagounidis and Xuena Wang and Robert R Deuson},
  journal={American journal of hematology},
  year={2012},
  volume={87 5},
  pages={
          558-61
        }
}
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by platelet destruction and insufficient platelet production. The resulting thrombocytopenia reduces patient health-related quality of life (HRQOL). In a randomized, open-label, 52-week study of non-splenectomized ITP patients treated with romiplostim or medical standard of care (SOC), patients completed the 10-scale ITP-patient assessment questionnaire (PAQ) at the start of the study and after 12, 24, 36, 48,and 52 weeks of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Immune thrombocytopenia: improving quality of life and patient outcomes

  • Patient related outcome measures
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND